A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. [electronic resource]
Producer: 19931126Description: 2624-33 p. digitalISSN:- 0006-4971
- Adult
- Aged
- Animals
- Antibodies, Anti-Idiotypic -- blood
- Antibodies, Monoclonal -- therapeutic use
- Antigens, CD -- immunology
- Antigens, Differentiation, B-Lymphocyte -- immunology
- Blood Cells -- drug effects
- Cell Adhesion Molecules
- Female
- Humans
- Immunotoxins -- adverse effects
- Lectins
- Lymphoma, B-Cell -- therapy
- Male
- Mice
- Middle Aged
- Ricin -- immunology
- Sialic Acid Binding Ig-like Lectin 2
- Vascular Diseases -- etiology
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
There are no comments on this title.
Log in to your account to post a comment.